Related Experiment Video
Updated: May 23, 2025

05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
17.7K
Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV
Geoffroy Liegeon1, Christopher Kaperak1, Eleanor E Friedman1
1Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Open Forum Infectious Diseases
|March 12, 2025
Abstract:
We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.

